Department of Ophthalmology, Emory University, Atlanta, Georgia, USA.
Ocul Immunol Inflamm. 2011 Jun;19(3):210-1. doi: 10.3109/09273948.2011.568661.
The fluocinolone acetonide (Retisert™) implant is an approved therapy for chronic, posterior, non-infectious uveitis. Continued episodes of inflammation can occur in patients after device implantation and suspected Retisert™ malfunction has been previously reported. We report a case of a patient who continued to have inflammation after Retisert™ implantation, which subsided after device exchange with a normally functioning explant after detailed manufacturer analysis.
氟轻松(Retisert™)植入剂是一种已获批的用于治疗慢性、后部、非传染性葡萄膜炎的疗法。在器械植入后,患者仍可能会出现持续的炎症发作,此前曾有报道怀疑 Retisert™ 发生故障。我们报告了一例患者在植入 Retisert™ 后仍持续存在炎症,在详细的制造商分析后,用正常工作的植入物进行器械更换后,炎症消退。